Dana-Farber Cancer Institute investigators presented Phase 2 CAR-PRISM data using CAR T-cell therapy in high-risk smoldering multiple myeloma, a precursor stage aimed at preventing progression. In the trial update, all 20 treated patients achieved no detectable myeloma cells after therapy, generating a deeper-than-usual response profile. The study tests whether immune interception at an earlier disease stage can redefine treatment goals compared with current standard approaches. The findings were discussed alongside the context that the only approved therapy for high-risk smoldering myeloma is the antibody daratumumab, which typically requires longer treatment courses. If the durability holds, the results could strengthen the case for moving CAR T earlier in the myeloma timeline, though investigators and outside experts continue to emphasize the need for longer follow-up and defined endpoints.